Robert Brusatti
Optometrist · Saint Louis, MONPI 1568460723
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $16,999 of the $19,535 with a category attached, or 87.0%. It is spread thinly across 25 manufacturers, the largest accounting for just 22.0% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $5,640, 4.7 times the $1,188 reported in 2019. Among optometrist clinicians in MO with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 576 payments — averaging $33.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$4K
- Bausch & Lomb Americas Inc.$4K
- Biotissue Holdings Inc.$2K
- Sun Pharmaceutical Industries Inc.$1K
- Novartis$1K
- Oyster Point Pharma, Inc.$997
- plus $6K from 19 others
Across 3 payments — averaging $297.09 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Dompe US, Inc.$891
What the payments were for
- Consulting fees$2,50013%
- Speaking & faculty fees$280%
- Food & beverage$16,99987%
- Education$80%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 188 | $4,303 |
| Bausch & Lomb Americas Inc. | 40 | $3,925 |
| Biotissue Holdings Inc. | 26 | $1,631 |
| Sun Pharmaceutical Industries Inc. | 36 | $1,375 |
| Novartis | 92 | $1,154 |
| Oyster Point Pharma, Inc. | 21 | $997 |
| Glaukos Corporation | 12 | $899 |
| Tarsus Pharmaceuticals, Inc. | 16 | $752 |
| Alcon | 23 | $735 |
| Dompe US, Inc. | 16 | $627 |
| Kala Pharmaceuticals, Inc. | 22 | $574 |
| Harrow Eye, LLC | 27 | $519 |
| Eyevance Pharmaceuticals LLC | 12 | $420 |
| Rxsight Inc | 4 | $305 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 10 | $271 |
| Mallinckrodt Hospital Products Inc. | 7 | $267 |
| Amgen | 4 | $186 |
| Thea Pharma Inc. | 8 | $171 |
| UCB, Inc. | 1 | $125 |
| ANI Pharmaceuticals, Inc. | 5 | $118 |
| Johnson & Johnson Vision Care, Inc. | 2 | $66 |
| Coopervision Inc. | 1 | $63 |
| Tearlab Corp | 1 | $18 |
| Ocular Therapeutix, Inc. | 1 | $18 |
| Shire North American Group Inc | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MIEBO$3,127
- DURYSTA$959
- CEQUA$865
- XIIDRA$748
- Prokera$664
- AmnioGraft$664
- TYRVAYA$599
- XDEMVY$570
- iDose$288
- iStent Inject Trabecular Micro-Bypass System$276
- VYZULTA$250
- TRYPTYR$244
- INVELTYS$230
- Oxervate$224
- Photrexa$145
- Hydrus Microstent$145
- GSW-iStentinjectWTrabecular Micro-Bypass System$138
- RXSIGHT CONTACT LENS$138
- RXSIGHT INJECTOR CARTRIDGE$138
- RXSIGHT INJECTOR HANDPIECE$138
How this compares
$19,535 in reported general payments places this provider in the 95th percentile of 1,030 optometrist providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XiidraLifitegrast | 375 | $518,386 |
| RestasisCyclosporine | 356 | $485,198 |
| LumiganBimatoprost | 587 | $342,694 |
| MieboPerfluorohexyloctane/Pf | 81 | $72,785 |
| XdemvyLotilaner | 36 | $68,511 |
| VyzultaLatanoprostene Bunod | 86 | $45,066 |
| Cyclosporine | 66 | $44,217 |
| RocklatanNetarsudil Mesylat/Latanoprost | 61 | $40,407 |
| VevyeCyclosporine | 46 | $34,721 |
| CombiganBrimonidine Tartrate/Timolol | 70 | $31,833 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 66 | $27,642 |
| Lotemax SmLoteprednol Etabonate | 97 | $27,124 |
| CequaCyclosporine | 26 | $24,438 |
| RhopressaNetarsudil Mesylate | 35 | $17,681 |
| Alphagan PBrimonidine Tartrate | 18 | $11,520 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan, Combigan, Alphagan P | $4,303 | $871,2461,031 claims |
| Bausch & Lomb Americas Inc.Xiidra, Miebo, Vyzulta | $3,925 | $636,236542 claims |
| Tarsus Pharmaceuticals, Inc.Xdemvy | $752 | $68,51136 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLotemax Sm, Prolensa, Loteprednol Etabonate | $271 | $39,301146 claims |
| Harrow Eye, LLCVevye | $519 | $34,72146 claims |
| AlconSimbrinza | $735 | $27,64266 claims |
| Sun Pharmaceutical Industries Inc.Cequa | $1,375 | $24,43826 claims |
| Eyevance Pharmaceuticals LLCFlarex | $420 | $1,99113 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,030 optometrist providers in Missouri.
Other optometrist in Saint Louis
- John McGrealSaint Louis$126K
- Ariel CerenzieSaint Louis$76K
- Paul LuongSaint Louis$44K
- Robert EnsleySaint Louis$38K
- Andrew RoyerSaint Louis$23K
- Edward BennettSaint Louis$13K
- Craig SorceSaint Louis$8K
- Julie DekinderSaint Louis$8K
- Erin SullivanSaint Louis$6K
- Kathryn NoonanSaint Louis$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.